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A B S T R A C T
Background
Tuberculosis (TB) requires at least sixmonths of treatment. If treatment is incomplete, patientsmay not be cured and drug resistancemay
develop. Directly Observed Therapy (DOT) is a specific strategy, endorsed by the World Health Organization, to improve adherence
by requiring health workers, community volunteers or family members to observe and record patients taking each dose.
Objectives
To evaluate DOT compared to self-administered therapy in people on treatment for active TB or on prophylaxis to prevent active
disease. We also compared the effects of different forms of DOT.
Search methods
We searched the following databases up to 13 January 2015: the Cochrane Infectious Diseases Group Specialized Register; the Cochrane
Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE; EMBASE; LILACS and mRCT.
We also checked article reference lists and contacted relevant researchers and organizations.
Selection criteria
Randomized controlled trials (RCTs) and quasi-RCTs comparing DOT with routine self-administration of treatment or prophylaxis
at home.
Data collection and analysis
Two review authors independently assessed risk of bias of each included trial and extracted data. We compared interventions using risk
ratios (RR) with 95% confidence intervals (CI). We used a random-effects model if meta-analysis was appropriate but heterogeneity
present (I2 statistic > 50%). We assessed the quality of the evidence using the GRADE approach.
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Main results
Eleven trials including 5662 participants met the inclusion criteria. DOT was performed by a range of people (nurses, community
health workers, family members or former TB patients) in a variety of settings (clinic, the patient’s home or the home of a community
volunteer).
DOT versus self-administered
Six trials from South Africa, Thailand, Taiwan, Pakistan and Australia compared DOT with self-administered therapy for treatment.
Trials included DOT at home by family members, community health workers (who were usually supervised); DOT at home by
health staff; and DOT at health facilities. TB cure was low with self-administration across all studies (range 41% to 67%), and direct
observation did not substantially improve this (RR 1.08, 95% CI 0.91 to 1.27; five trials, 1645 participants, moderate quality evidence).
In a subgroup analysis stratified by the frequency of contact between health services in the self-treatment arm, daily DOTmay improve
TB cure when compared to self-administered treatment where patients in the self-administered group only visited the clinic every
month (RR 1.15, 95% CI 1.06 to 1.25; two trials, 900 participants); but with contact in the control becoming more frequent, this
small effect was not apparent (every two weeks: RR 0.96, 95% CI 0.83 to 1.12; one trial, 497 participants; every week: RR 0.90, 95%
CI 0.68 to 1.21; two trials, 248 participants).
Treatment completion showed a similar pattern, ranging from 59% to 78% in the self-treatment groups, and direct observation did
not improve this (RR 1.07, 95% CI 0.96 to 1.19; six trials, 1839 participants, moderate quality evidence).
DOT at home versus DOT at health facility
In four trials that compared DOT at home by family members, or community health workers, with DOT by health workers at a
health facility there was little or no difference in cure or treatment completion (cure: RR 1.02, 95% CI 0.88 to 1.18, four trials, 1556
participants, moderate quality evidence; treatment completion: RR 1.04, 95% CI 0.91 to 1.17, three trials, 1029 participants, moderate
quality evidence).
DOT by family member versus DOT by community health worker
Two trials compared DOT at home by family members with DOT at home by community health workers. There was also little or
no difference in cure or treatment completion (cure: RR 1.02, 95% CI 0.86 to 1.21; two trials, 1493 participants, moderate quality
evidence; completion: RR 1.05, 95% CI 0.90 to 1.22; two trials, 1493 participants, low quality evidence).
Specific patient categories
A trial of 300 intravenous drug users in the USA evaluated direct observation with no observation in TB prophylaxis to prevent active
disease and showed little difference in treatment completion (RR 1.00, 95% CI 0.88 to 1.13; one trial, 300 participants, low quality
evidence).
Authors’ conclusions
From the existing trials, DOT did not provide a solution to poor adherence in TB treatment. Given the large resource and cost
implications of DOT, policy makers might want to reconsider strategies that depend on direct observation. Other options might take
into account financial and logistical barriers to care; approaches that motivate patients and staff; and defaulter follow-up.
P L A I N L A N G U A G E S U M M A R Y
Directly observing people with TB take their drugs to help them complete their treatment
This Cochrane Review summarises trials evaluating the effects of directly observed therapy (DOT) for treating people with tuberculosis
(TB) or people on prophylaxis to prevent active disease compared to self-administered treatment. After searching for relevant trials up
to 13 January 2015, we included 11 randomized controlled trials, enrolling 5662 people with TB, and conducted between 1995 and
2008.
What is DOT and how might it improve treatment outcomes for people with TB
DOT is one strategy to ensure that patients with TB take all their medication. An ’observer’ acceptable to the patient and the health
system observes the patient taking every dose of their medication, and records this for the health system to monitor.
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The World Health Organization currently recommends that people with TB are treated for at least six months to achieve cure. These
long durations of treatment can be difficult for patients to complete, especially once they are well and need to return to work. Failure
to complete treatment can lead to relapse and even death in individuals, and also has important public health consequences, such as
increased TB transmission and the development of drug resistance.
What the research says
Overall, cure and treatment completion in both self-treatment and DOT groups was low, and DOT did not substantially improve this.
Small effects were seen in a subgroup of studies where the self-treatment group were monitored less frequently than the DOT group.
There is probably no difference in TB cure or treatment completion when the direct observation was conducted at home or at the
clinic (moderate quality evidence). There is probably little or no difference in TB cure direct observation is conducted by a community
health worker or family member (moderate quality evidence) and there may be little or no difference in treatment completion either
(low quality evidence).
Direct observation may have little or no effect on treatment completion in injection drug users (low quality evidence).
The authors conclude that DOT on its own may not offer the solution to poor adherence in people taking TB medication.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Directly observed therapy (DOT) versus self-administered TB treatment
Patient or population: Patients on TB treatment
Settings: Low-, middle- or high-income countries
Intervention: DOT
Comparison: Self-administered therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Self-administered therapy DOT
Cure
Follow-up: up to 6 months
617 per 1000 666 per 1000
(561 to 784)
RR 1.08
(0.91 to 1.27)
1645
(5 trials)
⊕⊕⊕©
moderate 1,2,3,4
Treatment completion
Follow-up: 2 to 8 months5
709 per 1000 751 per 1000
(680 to 829)
RR 1.07
(0.96 to 1.19)
1839
(6 trials)
⊕⊕⊕©
moderate 1,2,3,4
The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; DOT: directly observed therapy; TB: tuberculosis.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1No serious risk of bias: three trials adequately described allocation concealment. Exclusion of trials at unclear or high risk of bias did
not substantially change the result.
2Downgraded by 1 for inconsistency: trials include qualitative differences in effect size and direction. The benefit reached standard levels
of statistical significance in the two trials where those receiving self-administered therapy had less frequent contact with health services
compared to the directly observed group, so any effect probably due to confounding.
3No serious indirectness: The trials were conducted in low-, middle- and high-income countries between 1995 and 2008.
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4No serious imprecision: The analysis is adequately powered to detect clinically important differences between treatment arms.
5Some trials checked for completion of intensive phase treatment and others the completion of the whole therapy, hence the 2 to 8
months.
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B A C K G R O U N D
Description of the condition
Tuberculosis (TB) remains a leading cause of death in low- and
middle-income countries despite the availability of effective treat-
ments. In 2012, the World Health Organization (WHO) esti-
mated that there were 8.6 million people infected with TB, of
whom 1.3 million died (WHO 2013). Most people infected with
Mycobacterium tuberculosis develop ’latent TB’, where the bacteria
are contained by the person’s immune system and they do not de-
velop symptoms. The risk of progression to active TB and devel-
opment of symptoms is about 10% over the course of a lifetime
(Frieden 2003), but co-infection with human immune deficiency
virus (HIV) increases this risk to about 10% per year (Sepkowitz
1995).
TheWHO currently recommends at least six months of treatment
for active disease, and 12 months for latent TB (Smieja 2010;
WHO 2010). These long durations of treatment can be difficult
for patients to adhere to, especially once they are well and need
to return to work. Poor adherence can lead to relapse and even
death in individuals, and also has important public health conse-
quences, such as increased transmission and the development of
drug resistance (Hirpa 2013; Moonan 2011).
Munro 2007 synthesized evidence from qualitative studies among
patients and health workers and identified eight factors that influ-
ence adherence:
1. Organization of treatment and care for TB patients.
2. Interpretation of illness and wellness by the patient.
3. Financial cost.
4. Patient knowledge, attitudes and beliefs about treatment.
5. Law and immigration status.
6. Gender and substance abuse.
7. Drug side effects.
8. Influence of the family, community and peers.
We adapted an existing conceptual framework by van den
Boogaard 2012 to develop a model for understanding approaches
to improving adherence (Figure 1).There are health system level
barriers (staff, inconvenient location, expensive and a poorly or-
ganized healthcare system) and personal level barriers (stigmati-
sation, poverty, competing demands and health beliefs) to adher-
ence and the patient has to work through these barriers in order
to be adherent. Healthcare workers have devised several strategies
targeted at some of the key barriers to improve adherence, some
of which are addressed by Cochrane Reviews:
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Figure 1. Factors influencing adherence and possible intervention points.
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• Reminder systems and late patient tracers in the diagnosis
and management of TB (Liu 2008).
• Patient education and counselling for promoting adherence
to treatment for TB (M’Imunya 2012).
• Material incentives and enablers in the management of TB
(Lutge 2012).
• Contracts: written or verbal agreements to return for an
appointment or course of treatment (Bosch-Capblanch 2007).
Description of the intervention
’Directly observed therapy’ (DOT) is one component of a wider
WHO strategy called ’Directly Observed Therapy Short course’
(DOTS). This strategy incorporates wide ranging health sys-
tem improvements, political commitment to improving TB pro-
grammes, improved TB laboratory services, free TB drugs for all
TB patients, and accurate documentation and monitoring of TB
diagnosis and treatment outcomes (WHO2002). TheDOT com-
ponent is an attempt to improve adherence by active monitoring
and recording of the consumption of each and every drug dose
by an ’observer’ acceptable to the patient and the health system
(Hopewell 2006). This approach was first adopted in studies in
Madras, India and Hong Kong as early as the 1960s (Bayer 1995),
and is now considered a core component of TB programmes by
the WHO to ensure cure and prevent the emergence of drug re-
sistance (Chien 2013; Hirpa 2013). Proponents of DOT argue
that the close monitoring has a social effect and acts as a peer pres-
sure which leads to behavior change towards improved adherence
(Macq 2003) and it has strong proponents (Chaulk 1998; Frieden
2007). However, to opponents it has been seen as a coercive model
which leaves the patient as a passive recipient of therapy thereby
eroding the gains made in involving patients in management of
their own health (Zwarenstein 1998 ZAF).
The initial Cochrane Review (Volmink 1997) and subsequent up-
dates (Volmink 2000a; Volmink 2001; Volmink 2003; Volmink
2006; Volmink 2007) challenged the dogma that DOT improved
cure and thus helped prevent drug resistance developing. The de-
bate has continued, with some even advocating for a shift of re-
sources away fromDOT programmes (Barbara 2013; Gross 2009;
Moonan 2011; Pasipanodya 2013). There are also debates as to the
best delivery of DOT, for example, should it be through health-
care workers or family members (Anuwatnonthakate 2008; Dick
2005).
Why it is important to do this review
Full implementation of DOT requires considerable resources. For
example, in Pakistan it has been shown that direct observation at a
health facility costs two timesmore than self-supervision (USD310
versus USD164). Therefore, it is important to evaluate the effects
in order to inform decisions about whether the benefits are worth
investing in (Khan 2003). This Cochrane Review is an update of
Volmink 2007.
O B J E C T I V E S
To evaluateDOTcompared to self-administered therapy in people
on treatment for active TB or on prophylaxis to prevent active
disease. We also compare the effects of different forms of DOT.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Individually randomized controlled trials (RCTs) or cluster-RCTs.
We also included quasi-RCTs.
Types of participants
People on treatment for active TB or receiving prophylaxis to
prevent the development of active TB disease.
Types of interventions
Intervention
DOT where a health worker, community volunteer or family
member, routinely observes participants taking their antitubercu-
lous drugs.
Control
Self-administered therapy or an alternative form of DOT.
Types of outcome measures
Primary
• Cure (having a negative sputum smear test in the last
month of treatment having been smear-positive initially).
• Treatment completion.
• Development of clinical TB (in trials of drug prophylaxis).
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Secondary
• Proportion of outpatient appointments attended.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press and in
progress).
Databases
We searched the following databases using the search terms
and strategy described in Appendix 1: Cochrane Infectious Dis-
eases Group (CIDG) Specialized Register (13 January 2015); the
Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library; MEDLINE (1966 to 13 Jan-
uary 2015); EMBASE (1974 to 13 January 2015); and LILACS
(1982 to 13 January 2015). We also searched the metaRegister of
Controlled Trials (mRCT) using ’tuberculosis AND DOT*’ (13
January 2015).
Researchers and organizations
For unpublished and ongoing trials, we contacted individual re-
searchers working in the field and the following organizations:
WHO, the International Union Against Tuberculosis and Lung
Disease, and the Centers for Disease Control and Prevention
(CDC).
Reference lists
We also checked the reference lists of all studies identified by the
above methods.
Data collection and analysis
Selection of studies
We independently applied the inclusion criteria to all identified
trials. We used the titles and abstracts of the identified citations to
exclude trials that clearly did not meet the inclusion criteria. If ei-
ther review author judged that the trial might be eligible for inclu-
sion, we obtained the full text article. We independently screened
the full text articles of selected trials to confirm eligibility and re-
solved any disagreements by discussion.
Data extraction and management
We independently extracted the data and checkedwhether trial au-
thors had conducted an intention-to-treat analysis. We contacted
trial authors to obtain missing information and to clarify issues.
We resolved discrepancies through discussion. For the outcomes,
we extracted the number of participants experiencing the event.
Assessment of risk of bias in included studies
We independently evaluated the methodological quality of each
trial, classifying the generation of allocation sequence and con-
cealment of allocation as either adequate, inadequate or unclear,
according to Jüni 2001. We classified blinding as adequate if the
trial authors took steps to ensure the people recording the main
outcome of the trial were blinded to the assigned interventions,
and inadequate if this was not the case or if there was no mention
of attempts to blind the observers. We assessed completeness of
follow-up as adequate if 90% or more of the enrolled participants
had outcome data reported, inadequate if less than 90% of the
participants had outcome data reported, or unclear if not men-
tioned in the trial.
Measures of treatment effect
For dichotomous outcomes, we calculated the results using the risk
ratio (RR).We presented the effect estimates with 95% confidence
intervals (CIs).
Assessment of heterogeneity
We looked for statistical heterogeneity by inspecting the forest
plots for overlapping CIs, applying the Chi2 test (P value < 0.10
considered statistically significant) and the I2 statistic (I2 value of
50% used to denotemoderate levels of heterogeneity).We assessed
whether a difference in the intensity of supervision between the
intervention and control group could explain heterogeneity.
Data synthesis
We used Review Manager 5 to analyse the data, using risk ratio
(RR) with 95% CIs to assess estimates of effect.We used the fixed-
effectmodel when there was no statistically significant heterogene-
ity (Chi2 test, P > 0.1) and a random-effects model when hetero-
geneity was present (I2 statistic > 50). We assessed the quality of
the evidence using the GRADE approach.
R E S U L T S
Description of studies
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Eleven trials, enrolling 5662 participants, met the inclusion cri-
teria (see ’Characteristics of included studies’), and we excluded
13 studies for the reasons listed in the ’Characteristics of excluded
studies’ table.
Nine included trials were individually RCTs, and two were cluster-
RCTs (Lwilla 2003 TZA; Newell 2006 NPL). One trial used a
quasi-random method of allocation (MacIntyre 2003 AUS).
Three trials were conducted in low-income countries (Tanza-
nia: Lwilla 2003 TZA; Wandwalo 2004 TZA; Nepal: Newell
2006 NPL); six in middle-income countries (Taiwan: Hsieh 2008
TWN; Pakistan: Walley 2001 PAK; Thailand: Kamolratanakul
1999 THA; South Africa: Zwarenstein 1998 ZAF; Zwarenstein
2000ZAF; andSwaziland:Wright 2004 SWZ); and twowere from
high-income countries (Australia: MacIntyre 2003 AUS; USA:
Chaisson 2001 USA).
Populations targeted
Ten trials evaluated DOT in people on treatment for active TB,
and one evaluated directly observed prophylaxis in intravenous
drug users (see Table 1; Table 2; Table 3).
Six trials compared DOT with self-administered therapy:
• Zwarenstein 1998 ZAF included two arms in two locations
(Elsies River and Khayelitsha); Zwarenstein 2000 ZAF was the
same trial containing data from one of these two locations, and
had an additional arms (lay health worker administered DOT).
The control arms (self-administered treatment) were therefore
the same for Elsies River in both trials, and so in the meta-
analysis we adjusted the data to ensure they were not counted
twice.
• Kamolratanakul 1999 THA allowed participants to choose
between DOT by a health worker, community leader or family
member; 85% chose the latter.
• Walley 2001 PAK compared DOT by a health worker or
community health worker with DOT by a family member and
with self-administration of treatment.
• MacIntyre 2003 AUS evaluated DOT by a family member
compared to self-administration.
• Hsieh 2008 TWN had DOT by case managers; there were
three arms; weekly observation, monthly observation and the
control group was patients admitted to hospital (Inpatient care).
Four trials compared different forms of DOT:
• Newell 2006 NPL compared community health worker
observation to family member observation.
• Wandwalo 2004 TZA trials compared DOT by a family
member with either DOT by a health worker at a health facility
or DOT by a community health worker.
• Wright 2004 SWZ compared community health worker
observation to family member observation coupled with a once
per week visit by a community health worker.
• Lwilla 2003 TZA compared a community health worker
DOT at home to DOT at a health facility.
One trial evaluated DOT in injecting (intravenous) drug users in
the USA:
• Chaisson 2001 USA involved intravenous drug users, and
studied DOT by an outreach nurse with self-administration
either with monthly peer support or monthly clinic visits.
Intensity of supervision
Intensity of supervision varied in the included trials. For the six
RCTs of DOT compared to self-administered treatment, three
trials appeared to be a direct comparison of healthcare worker
administered DOT versus self-administered. Another three trials
appeared to have more intense supervision in the DOT arm only,
with health workers visiting patients at home every two weeks.
In Kamolratanakul 1999 THA, community health workers and
family members received additional supervision by health centre
staff once every two weeks. In MacIntyre 2003 AUS, nurses had
weekly calls to the patients who were observed by familymembers.
In Hsieh 2008 TWN the case manager visited the patients in
the intervention arm and was supervised by weekly unscheduled
supervision. In the control group of these trials no such intensive
supervision was described.
Adjustment for clustering
Both cluster-RCTs adjusted for clustering appropriately: standard
error of the coefficients for clustering on units corrected using
the Huber-White-Sandwich method (Lwilla 2003 TZA); and, in
Newell 2006 NPL, using the coefficient of variation between clus-
ters.
Risk of bias in included studies
We have summarized the ’Risk of bias’ assessments Figure 2 and
Figure 3, and have listed the reasons in the Characteristics of
included studies section.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
Allocation
Seven trials used adequatemethods to generate a random sequence:
computer-generated random sequences (Chaisson 2001 USA;
Walley 2001 PAK; Zwarenstein 1998 ZAF; Zwarenstein 2000
ZAF), a random-number table (Kamolratanakul 1999THA), coin
tossing (Wandwalo 2004 TZA) or drawing of lots from a basket
(Newell 2006 NPL). One trial used alternate allocation, which
was an inadequate randomizationmethod (MacIntyre 2003 AUS).
The remaining trials reports did not provide information (Hsieh
2008 TWN; Lwilla 2003 TZA; Wright 2004 SWZ).
Four trials employed adequate methods for concealing allocation
(Newell 2006 NPL; Walley 2001 PAK; Zwarenstein 1998 ZAF;
Zwarenstein 2000 ZAF). Five trials had unclear allocation conceal-
ment (Chaisson 2001 USA; Hsieh 2008 TWN; Kamolratanakul
1999 THA; Lwilla 2003 TZA; Wright 2004 SWZ) and the re-
maining two trials did not use allocation concealment (MacIntyre
2003 AUS; Wandwalo 2004 TZA).
Blinding
Only four trials blinded outcome assessment (MacIntyre 2003
AUS;Newell 2006NPL;Walley2001 PAK;Wright 2004 SWZ). It
was not used in three trials (Chaisson 2001 USA; Kamolratanakul
1999 THA; Lwilla 2003 TZA) and unclear in the remaining trials
(Hsieh 2008 TWN; Wandwalo 2004 TZA; Zwarenstein 1998
ZAF; Zwarenstein 2000 ZAF).
Incomplete outcome data
Two trials excluded more than 10% of participants from the
analyses (Lwilla 2003 TZA; Zwarenstein 1998 ZAF). A further
three trials did not provide sufficient information to assess this
aspect of trial quality (MacIntyre 2003 AUS; Newell 2006 NPL;
Zwarenstein 2000 ZAF). The remaining trials had adequate fol-
low-up.
Selective reporting
We found no evidence of selective reporting.
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Other potential sources of bias
Hsieh 2008 TWN had a control group which was inpatient based.
We have not included this group in our analyses. Two trials had the
same control groups (Zwarenstein 1998 ZAF; Zwarenstein 2000
ZAF; see Table 1).
Lwilla 2003 TZA had one cluster in the community observed arm
lost to follow-up and we therefore did not include it in the final
analysis. Two cluster-RCTs had cluster adjustment.
Effects of interventions
See: Summary of findings for the main comparison Directly
observed therapy (DOT) versus self-administered TB treatment;
Summary of findings 2 Home DOT versus clinic DOT;
Summary of findings 3 Summary of findings table 3; Summary
of findings 4 DOT versus self-administered therapy for
intravenous drug users
1. DOT versus self-administered therapy
The details of the interventions are described in Table 1; and see
Summary of findings for the main comparison.
Six trials compared DOT and self-administered therapy. The ob-
servers were described as either nurses (Zwarenstein 1998 ZAF;
Zwarenstein 2000 ZAF), healthcare workers (Kamolratanakul
1999 THA; Walley 2001 PAK), community health workers
(Kamolratanakul 1999 THA;Walley 2001 PAK), lay healthwork-
ers (Zwarenstein 2000 ZAF), case managers (Hsieh 2008 TWN)
or family members (Kamolratanakul 1999 THA;MacIntyre 2003
AUS;Walley 2001 PAK). In one trial participants were allowed to
choose either a healthcare worker, a community health worker or
a family member (Kamolratanakul 1999 THA).
Overall TB cure was low with self-administered therapy, ranging
from 41% to 69% across trials, but on average this did not sub-
stantially improve with DOT (RR 1.08, 95% CI 0.91 to 1.27;
five trials, 1645 participants, moderate quality evidence; Analysis
1.1). However, there was moderate statistical heterogeneity be-
tween trials (I2 statistic = 68%; P = 0.01), with two trials finding
benefits which reached standard levels of statistical significance
(Kamolratanakul 1999 THA; Hsieh 2008 TWN). These differ-
ential effects may be explained by differences in the intensity of
follow-up between the intervention and control arms (Analysis
1.2). However it is important to note that these two trials were
also at unclear or high risk of selection bias and detection bias.
Kamolratanakul 1999 THA is the largest trial of DOT to date
and found a higher TB cure with the intervention (76% versus
67%; RR 1.13, 95% CI 1.04 to 1.24; one trial, 836 participants).
This trial had the least supervised control group (patients picked
up their medication monthly), and one of the most intensely su-
pervised intervention groups (doses were directly observed daily
by a choice of health worker, community health worker or family
member, and a health worker visited the patient at home every
two weeks to check on adherence). This difference in intensity
was similar in the second trial showing a difference (94% versus
69%; RR 1.36, 95% CI 1.06 to 1.75; one trial, 64 participants),
but this trial was small and underpowered to have full confidence
in this effect (Hsieh 2008 TWN).
Similarly, TB treatment completion ranged from 59% to 78%
in those allocated to self-administration, and on average did not
substantially improve with DOT (RR 1.07, 95% CI 0.96 to 1.19;
six trials, 1839 participants, moderate quality evidence; Analysis
1.3). There was again moderate heterogeneity between trials (I2
= 57%; P = 0.04), with the same two trials finding statistically
significant benefits (Hsieh 2008 TWN; Kamolratanakul 1999
THA).
Different levels of monitoring in the self-administered groups did
not yield substantially different levels of completion. (Self-treat-
ment group: monthly monitoring RR 1.12, 95% 0.95 to 1.31;
three trials, 1073 participants; every two weeks: RR 0.99, 95%
0.87 to 1.14; one trial, 497 participants); weekly monitoring RR
1.04, 95% 0.74 to 1.46; two trials, 269 participants; Analysis 1.4).
2. Home observation versus clinic observation
The trials are described in Table 2; and see Summary of findings
2.
Four trials compared home with clinic observation. Two tested
family member direct observation against direct observation at
clinic (Walley 2001 PAK; Wandwalo 2004 TZA) while the other
two tested community health worker home visits to direct obser-
vation at clinic (Lwilla 2003 TZA; Zwarenstein 2000 ZAF).
TB cure was generally low for both the home observation groups
(ranging from 43% to 57%) and for clinic observation (ranging
from 41% to 64%). On average there was little or no difference
between the two strategies (RR 1.02, 95% CI 0.88 to 1.18; four
trials, 1556 participants, moderate quality evidence; Analysis 2.1).
Treatment completion ranged from 62% to 85% in those being
observed at home and between 57% and 83% in clinic observa-
tion. On average there was little or no difference between the two
locations (RR 1.04, 95% CI 0.91 to 1.17; three trials, 1034 par-
ticipants, moderate quality evidence; Analysis 2.2).
One trial, Lwilla 2003 TZA, had more intense supervision of
the observer than the other three trials. This intense supervision
however did not improve cure rates (53% for home observation
and 49% for clinic observation; RR 1.01, 95% CI 0.91 to 1.11;
four trials, 1556 participants, Analysis 2.3). This trial however did
not report on completion of treatment.
Wandwalo 2004 TZA had high completion rates (85% in home
and 83% in clinic observation arm) but the cure rates were quite
low in either arm (43% in both arms).
3. Community observed versus family observed
Two trials compared community health worker based observation
with family based observation (Newell 2006 NPL; Wright 2004
SWZ). The trials are described in Table 3.
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TheNepal trial, Newell2006NPL, had higher cure rates across the
two arms (85% for community and89%for family observed) com-
pared with Wright 2004 SWZ (68% for community and 61% for
family observed). There was little or no difference between com-
munity and family observation (RR 1.02, 95% CI 0.86 to 1.21;
two trials, 1493 participants, moderate quality evidence; Analysis
3.1). However there was high statistical heterogeneity (I2 = 86%;
P = 0.009).
Similarly, for the completion of treatment outcome Newell 2006
NPL had higher rates across the two arms (96% in both arms)
compared withWright 2004 SWZ (74% for community and 67%
for family observed). There was little or no difference between
community and family observation (RR 1.05, 95% CI 0.90 to
1.22; two trials, 1493 participants, low quality evidence; Analysis
3.2). Again there was high statistical heterogeneity (I2 = 87%; P =
0.005).
4. DOT versus self-administered therapy for
intravenous drug users
One trial, Chaisson 2001 USA, had three arms, supervision at
a clinic, peer group supervision and self-administered treatment.
The level of treatment completion was similar in those self-admin-
istering (79%) and those under peer or clinic supervision (79%)
(RR 1.00, 95% CI 0.88 to 1.13; one trial, 300 participants, low
quality evidence; Analysis 4.1).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Home DOT versus clinic DOT
Patient or population: Patients with TB treatment
Settings: Low-, middle- or high-income countries
Intervention: Home observation
Comparison: Clinic observation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Clinic observation Home observation
Cure
Follow-up: up to 6 months
492 per 1000 502 per 1000
(433 to 580)
RR 1.02
(0.88 to 1.18)
1556
(4 trials)
⊕⊕⊕©
moderate 1,2,3
Treatment completion 4
Follow-up: 2 to 6 months
751 per 1000 781 per 1000
(684 to 879)
RR 1.04
(0.91 to 1.17)
1029
(3 trials)
⊕⊕⊕©
moderate 1,2,3
The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; DOT: directly observed therapy; TB: tuberculosis.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 1 for risk of bias: selection bias is probable in one trial, Wandwalo 2004 TZA, as there was no blinding and no
allocation concealment. In Lwilla 2003 TZA, sequence generation and allocation concealment were unclear and there was no blinding.
This could bias the measurement of treatment completion.
2No serious indirectness: The trials were conducted in low-, middle- and high-income countries between 1995 and 2008.
3No serious imprecision: The analysis is adequately powered to detect clinically important differences between treatment arms.
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4Some trials checked for completion of intensive phase treatment and others the completion of the whole therapy, hence the 2 to 6
months.
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Community DOT versus family DOT
Patient or population: Patients on TB treatment
Settings: Low-, middle- or high-income countries
Intervention: Community DOT
Comparison: Family DOT
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Family DOT Community DOT
Cure
Follow-up: up to 6 months
766 per 1000 781 per 1000
(659 to 927)
RR 1.02 (0.86 to 1.21) 1493
(2 trials)
⊕⊕⊕©
moderate 1
Treatment completion
Follow-up: 2 to 6 months
827 per 1000 869 per 1000
(744 to 1000)
RR 1.05 (0.90 to 1.22) 1493
(2 trials)
⊕⊕©©
low 1,2
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; DOT: directly observed therapy; TB: tuberculosis.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 1 for risk of bias. Both trials had unclear random sequence generation and recruitment bias could not be ruled out for
Newell 2006 NPL.
2Downgraded by 1 for risk of bias for the outcome of treatment completion as there was no allocation concealment and selective
reporting could not be ruled out in Wright 2004 SWZ.
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DOT versus self-administered therapy for intravenous drug users
Patient or population: Patients on TB treatment
Settings: Low-, middle- or high-income countries
Intervention: DOT
Comparison: Self-administered treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Self-administered therapy DOT
Treatment completion
Follow-up for 6 months
79 per 100 79 per 1000
(70 to 89)
RR 1.00 (0.88 to 1.13) 300
(1 trial)
⊕⊕©©
low 1,2,3
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; DOT: directly observed therapy; TB: tuberculosis.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 1 for risk of bias. There was no blinding of outcome assessment and allocation concealment was unclear and treatment
completion can be a bit subjective hence the results might be biased. The level of completeness to follow-up was 88%.
2Downgraded by 1 for indirectness. The self-administered group had a 10 dollar stipend which is may have enhanced adherence in this
group.
3There may have been some imprecision. The study was had a small sample size and may have been underpowered to detect clinically
important differences.
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D I S C U S S I O N
Summary of main results
TB cure and treatment completion were low with self-adminis-
tered therapy in these trials, and direct observation did not sub-
stantially improve this. Positive effectswith direct observationwere
seen in two trials where patients in the control group were only
seen in clinic once a month, but not in the three trials where the
controls were seen more frequently (every one or two weeks).
Trials comparing home observation (community observer or fam-
ily observer) to clinic or healthcare worker led observation did not
show any difference in TB cure or treatment completion. Within
home-based direct observation, there were no differences between
direct observation by a family member and direct observation by
a community health worker.
Overall completeness and applicability of
evidence
This Cochrane Review includes trials from both high- and low-
burden countries, conducted between 1994 and 2008. Direct ob-
servationwas implemented in line with current recommendations,
and the findings remain applicable to TB treatment programmes
today.
Cure and treatment completion with self-administered treatment
were low in these trials, consistent with the outcomes seen in TB
programmes at the time, and consequently it is remarkable that
direct observation failed to substantially improve these.
One interpretation, offered by Frieden 2007, is that these trials
failed to implement direct observation effectively. This interpreta-
tion seems unreasonable to us, as the authors of the included trials
did what they could to implement direct observation, and it may
even be harder to implement, and less successful, outside of a clin-
ical trial . Alternative interpretations are that the health systems
were struggling to deliver TB treatment, and direct observation on
its own did not resolve these underlying issues, or that TB patients
experience financial or logistical barriers to compliance with direct
observation. For example, it may cost patients money if they have
to visit a health facility as was the case in Walley 2001 PAK.
Direct observation as a strategy is still debated in TB and other
chronic diseases. These debates and the findings of this review and
others are important given the often huge resource implications
of implementing a direct observation therapy programme. In two
studies conducted in Brazil to evaluate the cost effectiveness of
direct observation strategy; one reported a doubling of indirect
costs to the patient compared to self-administered therapy (Mohan
2007) while the other reported an incremental cost-effectiveness
ratio (ICER) of USD6616 per completed direct observed treat-
ment compared to self-administered therapy (Steffen 2010).
Agreements and disagreements with other
studies or reviews
The findings of this Cochrane Review are similar to the findings of
a meta-analysis by Pasipanodya 2013, who reported no difference
between DOT and self-administered treatment in terms of reduc-
tion in microbiological failure, adverse drug reactions acquired re-
sistance and relapses. The meta-analysis included ten studies, five
RCTs and five observational studies. However, it is worth noting
that the included trials were quite heterogenous for a meta-anal-
ysis, the quality scales used were quite unclear and their findings
were probably influenced by one observational study.
In their clinical review,Chan 2002 reported that direct observation
is essential and effective for treatment and, by extension, TB elim-
ination. The review was not systematic and mainly looked at areas
where DOT has been done in conjunction with other interven-
tions. It is probable that the other interventions or inputs, rather
than specifically observing a patient as they take their medication,
were beneficial for benefit, as highlighted by Volmink 2000b. A
review by Tian 2014 reported that direct observation at a clinic
was not more effective than self-treatment; but that community
direct observation may be, with no difference detected between
family and non-family direct observation. The review did not as-
sess the inputs and associated supervision to the extent that we did
in this Cochrane Review.
Ford 2009, a review of direct observation in HIV therapy, also
reported no effect on virological suppression. Though it might
be argued that the therapy of these two diseases is different given
that TB is for a finite duration whereas HIV is lifelong and thus
adherence issues are different.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available evidence indicates that direct observation, evenwhen
supervised by health staff, does not resolve poor adherence in TB
treatment. Given the huge cost implications of direct observation,
policy makers therefore might want to rethink their strategies for
improving adherence. It is probably worthwhile in considering
financial and logistical barriers to care, motivating patients and
staff, and enhancing defaulter tracing mechanisms.
Implications for research
The lack of effects of direct observation in improving cure and
completion rates is surprising but reflects the complexity of adher-
ence. Further research in well functioning health systems is needed
to assess alternative and complementary strategies to direct obser-
vation. Qualitative work focusing on defaulters, where defaulter
mechanisms exists and how clinicians interact with patients would
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especially be important. Evaluation of the cost of DOT for pa-
tients and providers would also help in properly assessing these
strategies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chaisson 2001 USA
Methods Generation of allocation sequence: randomized, with factorial overlay; computer-gener-
ated random numbers
Allocation concealment: not stated.
Blinding: none.
Completeness of follow-up: 88%.
Participants Number: 300 randomized; 73%men; 85% unemployed; 27%with documented human
immunodeficiency virus (HIV) infection
Included: adult, intravenous drug users with positive tuberculin skin test (at least 10 mm
induration or 5 mm if HIV positive); given isoniazid preventive therapy for 6 months
Excluded: people with active TB.
Interventions 1. DOT twice weekly by outreach nurse at clinic or community location.
2. Daily self-administration of treatment, monthly peer counselling group meetings
with lunch, and clinical assessments by a nurse; peer counsellor was a former injection
user who had completed preventive therapy, and who was trained in counselling and
supervised by a health educator.
3. Daily self-administration of treatment with monthly clinic assessment; factorial
design with immediate or deferred US$10 stipend at the end of each month; deferred
payments credited each month and given when treatment completed or participant
withdrew.
Outcomes 1. 6 months treatment completed, defined as 80% or more of treatments taken
(observed for DOT group and 6 monthly visits plus reporting that at least 80%
medication taken during a month for other groups).
2. Pill counts.
3. Isoniazid metabolites in the urine.
4. Electronically monitored bottle opening in a subset.
Notes Location: Baltimore City Health Department TB Clinic, USA.
Date: 1995 to 1997.
Duration of DOT duration not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “generated using computer algorithm”.
Allocation concealment (selection bias) Unclear risk No details reported.
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Chaisson 2001 USA (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk None. “Blinding of the study was not pos-
sible.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were losses to follow-up in each arm
though not differential there are no reports
on them
Selective reporting (reporting bias) Low risk All outcomes stated in themethodology are
reported.
Other bias Unclear risk Not applicable.
Hsieh 2008 TWN
Methods Generation of allocation sequence: not stated.
Randomization: stratified.
Allocation concealment: not stated.
Blinding: not stated.
Completeness of follow-up: no losses (18/114) dropped to enable matching
Participants Number; 96 randomized into three groups; Matched by age and gender; confirmed TB
diagnosis and over 18 yrs
Interventions 1. Case manager directly supervised medicine intake for first two months, then self-
administration with weekly unscheduled visit.
2. Self-administration with monthly unscheduled visit by the case manager.
3. Routine care in the ward with monthly visit by case manager.
Outcomes 1. Monthly adherence levels (>80% or <80%) >80% defined as at most 5 drug
interruptions per month.
2. Completion rate - Proportion of patients who completed the treatment course.
3. Success rate - Proportion of patients who completed treatment plus confirmed
negative sputum result.
Notes Location: Taiwan.
Trial period: May 2002 to July 2003.
Duration of observation was 6 months.
The patients were not given a choice of DOT observer.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “There were 114 subjects meeting the sam-
pling criteria who were then matched by
age and gender and randomized into one
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Hsieh 2008 TWN (Continued)
of three groups”
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 18/114 dropped to enable matching.
Selective reporting (reporting bias) Unclear risk All outcomes stated in themethodology are
reported.
Other bias Unclear risk Not applicable.
Kamolratanakul 1999 THA
Methods Generation of allocation sequence: central block random allocation scheme prepared for
each of 15 trial sites; random-number table used
Allocation concealment: none.
Blinding: no blinding of assessors.
Completeness of follow-up: 100% (no losses).
Participants Number: 837 randomized; 73% male.
Included: new smear positive adults (aged 15+).
Interventions 1. Daily supervision: participants chose their supervisor from (a) health centre staff,
(b) community members, or (c) family members; for (b) and (c) health workers visited
homes twice monthly (first 2 months) or monthly for checking of treatment cards, pill
counts, and urine tests.
2. Self-administration of treatment: 1 month drug supply given at diagnosis and
after each follow-up visit; no treatment supervision between visits.
All participants received the same drug regimen: isoniazid-rifampicin-pyrazinamide-
ethambutol for 2 months and isoniazid-rifampicin for 4 months
Outcomes 1. Cure rate (primary outcome): completed 6 months antituberculous therapy, with
2 negative sputum exams, 1 at end of treatment.
2. Treatment completion: completed 6 months antituberculous therapy but less than
2 sputum exams.
3. Sputum conversion rate: negative sputum at end of third month.
4. Percentage defaults.
5. Percentage transfers.
6. Caseholding rate.
Notes Location: Thailand.
Date: 1996 to 1997.
Duration of
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Kamolratanakul 1999 THA (Continued)
DOT not stated.
Informed consent not obtained as participants were not told that they were participating
in a study
Choice of supervisor for DOT participants: 352 chose a family member; 34 chose a
community member; and 24 chose health centre staff
One participant in daily supervision arm excluded due to protocol violation so not strictly
intention-to-treat
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated using random number tables.
Allocation concealment (selection bias) Unclear risk Inadequate information.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Investigators not blinded though the pa-
tients were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no exclusions.
Selective reporting (reporting bias) Unclear risk All outcomes stated in themethodology are
reported.
Other bias Unclear risk Not applicable.
Lwilla 2003 TZA
Methods Cluster-RCT: 9 pairs of centres matched by type and size.
Generation of allocation sequence: unclear.
Allocation concealment: unclear.
Blinding: none.
Completeness of follow-up: 87% at 2 months and 69% at 7 months
Participants Number: 18 clusters randomized; 522 participants; mean age 35; 60% male
Included: new smear positive adults.
Interventions 1. Community-based DOT: daily observation by community health volunteer (site
not stated) for intensive 2-month treatment period; health worker visited volunteer
every 2 weeks and district co-ordinator visited volunteer monthly; at each visit
participants’ treatment card checked and drugs counted.
2. Institution-based DOT: required to attend health facility daily for 2 months, and
then monthly after this.
Continuation phase of 6 months: both groups managed the same and expected to self-
administer treatment daily
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Lwilla 2003 TZA (Continued)
Outcomes 1. Sputum negative at 2 months (primary outcome).
2. Cure at 7 months (sputum negative at 2 months and at 5 to 7 months).
Notes Location: Tanzania.
Date: 1999 to 2000.
Duration of DOT not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details reported.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk None. “This studywas anunmasked cluster
randomized trial”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 68% (311/437 participants) were
evaluated at 7 months. (This could affect
the cure outcome)
Selective reporting (reporting bias) Low risk All outcomes stated in themethodology are
reported.
Recruitment bias Unclear risk No details of any shifting, though the clus-
ter sizes varied from as low as 2 persons to
232 persons
Baseline imbalance Low risk Clusters were similar though the size varied
and one cluster had possibly a more sicker
patient profile due to its highly specialized
nature
Loss of clusters Unclear risk One cluster in the community based in-
tervention did not have patients hence was
dropped in the analysis
Incorrect analysis Low risk Cluster adjusted hence comparable to other
RCTs randomizing individuals
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MacIntyre 2003 AUS
Methods Quasi-RCT
Generation of allocation sequence: alternate allocation
Concealment of allocation: none
Blinding: assessment of urinary isoniazid blinded
Completeness of follow-up: not stated
Participants Number: 173 recruited, mostly foreign nationals; male 51%; mean age 41 (range 14 to
83)
Included: new TB participants.
Excluded: multiple-drug resistant TB; relapsed TB; human immunodeficiency virus
(HIV)-positive cases; and nontuberculous mycobacterial infections
Interventions 1. Family-based DOT: daily observation by a nominated family member who
received education and was expected to record participant compliance with pill taking;
weekly phone calls from a nurse; nurse on call; nurse home visit every 2 weeks.
2. Self-administration of treatment: daily.
Both groups had monthly visits to health facilities and standardized recording charts
Outcomes Treatment completion measured by:
1. Percentage clinic attendances to collect drugs.
2. Urinary isoniazid (6 random checks over months; all had to be > 0).
Notes Location: Australia.
Date: 1998 to December 2000.
Duration of DOT not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not randomly. “Patients were systemati-
cally allocated to receive FDOT or ST”
Allocation concealment (selection bias) High risk Systematic allocation “The first patient was
randomly allocated to the ST arm, every
second patient was allocated to FDOT, and
the remainder to ST”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information as to what hap-
pened to those who refused family DOT
Selective reporting (reporting bias) Unclear risk All outcomes stated in themethodology are
reported.
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MacIntyre 2003 AUS (Continued)
Other bias Unclear risk Not applicable.
Newell 2006 NPL
Methods Cluster-RCT.
Generation of allocation sequence: 5 randomly selected districts allocated to each arm;
the name of each district was written on an individual paper and randomly drawn from
a basket
Allocation concealment: method not stated.
Blinding: laboratory technicians assessing the primary outcomes were blinded
Completeness of follow-up: 100% (no clusters or individuals lost)
Participants Number: 10 districts with 907 people randomized; all smear positive; 67% male
Included: people with TB (aged 15+); new smear-positive cases, diagnosed at health
facilities in the trial area; human immunodeficiency virus (HIV) status not known
Interventions 1. Community-based DOT: daily treatment supervised by a female community
health worker (unpaid volunteer selected by the district health authority) or village
health worker (community worker paid by government). Patients mainly visited at
home, but occasionally patients met their supervisor at her home. Supervision was for
the duration of treatment with drugs provided to the supervisor monthly. Tracing by
the supervisor was undertaken for patients who discontinued treatment.
2. Family-based DOT: daily supervision by a household member chosen by the
participant with drugs provided to the supervisory weekly. Government workers traced
those who discontinued treatment.
Outcomes 1. Treatment success: cure plus treatment completion (primary).
2. Treatment success compared with the WHO target of 85%.
3. Estimated case detection rate with the WHO target of 70%.
4. Compare the above rates in men and women.
Notes Location: hill and mountain districts of Nepal.
Date: 2002 to 2003.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information on selection of 10
districts out of 17
Allocation concealment (selection bias) Low risk Randomly picked papers from an opaque
bag.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded.
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Newell 2006 NPL (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No cluster was lost to follow-up or ex-
cluded.
Selective reporting (reporting bias) Low risk All outcomes stated in themethodology are
reported.
Recruitment bias Unclear risk Not reported if there were patients who
shifted to the different intervention arms,
though they were separated by a mountain-
ous region
Baseline imbalance Low risk Characteristics similar.
Loss of clusters Low risk No loss reported.
Incorrect analysis Low risk Cluster adjustment done.
Walley 2001 PAK
Methods Generation of allocation sequence: computer-generated random numbers
Allocation concealment: opaque, sealed envelopes.
Blinding: assessors blinded.
Completeness of follow-up: not stated.
Participants Number: 497 randomized; 51.3% male.
Included: adults (aged 15+); new smear-positive cases.
Interventions 1. DOT by a health worker at a health facility that met “access criteria” or a
community health worker at or near the participant’s home: access criteria were return
journey from the participant’s home to facility < 2 km, < 2 hr duration, and < 10
rupees, and for unmarried women an accompanying relative was available; participants
had to attend a health facility or meet a community health worker 6 times per week for
2 months to take their drugs; thereafter they self-administered drugs that the
participants collected twice a month.
2. DOT by a family member chosen by the participant.
3. Self-administration of drugs collected by participant fortnightly.
All participants received isoniazid-rifampicin-pyrazinamide-ethambutol for 2 months
and isoniazid-ethambutol for 6 months
Outcomes 1. Cure: sputum negative at 7 or 8 months and on at least 1 previous occasion.
2. Treatment completion: treatment completed, but smear results not available on at
least 2 occasions before completion of treatment.
3. Treatment failure.
4. Death.
5. Default.
6. Transferred out.
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Walley 2001 PAK (Continued)
Notes Location: Pakistan
Date: 1996 to 1998
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random sequence.
Allocation concealment (selection bias) Low risk Opaque envelopes were used and third
party calls.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no exclusions after randomiza-
tion.
Selective reporting (reporting bias) Low risk All outcomes stated in themethodology are
reported.
Other bias Unclear risk Not applicable.
Wandwalo 2004 TZA
Methods Generation of allocation sequence: coin tossing in each of 5 clinics
Allocation concealment: none.
Blinding: none.
Completeness of follow-up: 100% (no losses).
Participants Number: 587 randomized; 322 smear positive, 182 smear negative, and 83 extrapul-
monary TB; 57% male
Included: people with TB (aged 5+); new smear positive, smear negative, and extrapul-
monary cases; human immunodeficiency virus (HIV) status not known
Excluded: previously treated for TB; severe illness; transferred from another clinic; pre-
viously enrolled in the study
Interventions 1. Community-based DOT: daily treatment supervised at home by ’guardian’
(usually a family member) during 2-month intensive period; supervisors trained to
observe drug taking, encourage participants to complete treatment, keep records,
collect drugs, and assess drug side effects; during first 2 months participants received
’spot’ visits by health workers who conducted treatment card checks and pill counts;
during first 2 months participants also requested to attend clinic every 2 weeks for
clinical review and progress monitoring.
2. Health facility-based DOT: daily supervision at clinic by health workers during
the 2 month intensive period.
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Wandwalo 2004 TZA (Continued)
Apart from the observation option participants received the same standardized manage-
ment including drug therapy
Outcomes 1. Treatment success: cure plus treatment completion.
2. Cure: smear positive initially and negative at 7 or 8 months and on at least 1
previous occasion.
3. Treatment completion: positive results initially, negative at 2 months and no
results at end of treatment; or smear negative initially and received treatment on
clinical grounds; or those who completed full course of treatment but had no initial or
end-of-treatment results.
4. Death: from all causes.
5. Treatment failure: participants who remained or became smear positive or 5
months or later.
6. Default: failed to collect medication for > 2 consecutive months.
7. Transferred out: transferred to a clinic in another area.
Notes Location: Dar es Salaam, Tanzania.
Date: 2001 to 2003.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly by coin toss”.
Allocation concealment (selection bias) High risk None.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions.
Selective reporting (reporting bias) Low risk All outcomes stated in themethodology are
reported.
Other bias Unclear risk Not applicable.
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Wright 2004 SWZ
Methods Generation of allocation sequence: unclear; stratified into adults and children; then,
within each group, randomized by type of TB (sputum positive, sputum negative, ex-
trapulmonary, relapse)
Allocation concealment: unclear; sealed, sequentially numbered envelopes not stated if
opaque
Blinding: assessors of sputum results blinded.
Completeness of follow-up: 98%.
Participants Number: 1353 randomized; 55% male; most 15+ years.
Included: adults and children with smear positive or negative, extrapulmonary TB, or
relapse of previously treated TB
Excluded: died before discharge; or too ill to receive outpatient treatment; lived in area
without treatment supporter; or referred in after treatment commenced
Interventions 1. DOT by community health worker: participants visited for observation daily;
community health worker trained to provide daily treatment supervision, record
adherence on Treatment Support Card, remind participants who did not report for
treatment, and notify diagnostic centre about those who defaulted treatment.
2. DOT by family member: family member or carer chosen by participant trained to
provide daily treatment supervision, record adherence on Treatment Support Card, and
remind participants who did not report for treatment; participants also required to visit
the community health worker weekly to check side effects and adherence and receive
health education; defaulters reported to the diagnostic centre.
Outcomes 1. Cure or treatment completion: cure defined as smear negative at 6 months and on
at least 1 previous occasion; treatment completion defined as treatment completed but
smear results not available on at least 2 occasions before treatment completion.
2. Death.
3. Treatment failure: remained or became smear positive at ≥ 5 months.
4. Default: failed to collect medication for > 2 consecutive months.
5. Transferred out: formally transferred to another centre.
Notes Location: Swaziland.
Date: 2000 to 2002.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information.
Allocation concealment (selection bias) Unclear risk Use of sealed envelopes not clear whether
opaque. “
sealed, sequentially numbered, stratum
specific envelopes containing treatment as-
signments”
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Wright 2004 SWZ (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Non differential loss to follow-up (4/664
and 5/662).
Selective reporting (reporting bias) Unclear risk All outcomes stated in themethodology are
reported.
Other bias Unclear risk Not applicable.
Zwarenstein 1998 ZAF
Methods Generation of allocation sequence: computer-generated random numbers
Allocation concealment: consecutively numbered, opaque, sealed envelopes in each of 5
clinics
Blinding: none.
Completeness of follow-up: 114/120 (95%) in 1 trial and 102/120 (85%) in other trial
excluded from analysis
Participants Number: 216 included in analysis; 62% male; 57% < 35 years.
Included: adults (aged 15+) with pulmonary TB; both new and re-treatment cases
Excluded: severe disease or multiple drug resistance; treatment at a non-study clinic for
more than 2 weeks; need to be supervised at school or at the workplace; and leaving the
area within a month
Interventions 1. DOT by clinic nurses: participants asked to visit the clinic 5 days a week for 8
weeks (new participants) or for 12 weeks (re-treatment participants); thereafter
expected attendance was 3 days a week for the continuation phase; clinic visits
restricted to normal working hours and adherence card signed and dated by a nurse at
each visit and kept at the clinic.
2. Self-administration of treatment: participants had to visit clinic once a week or
send a relative to collect drugs; participants completed their own adherence card for
every day of drug taking and a nurse recorded the weekly drug collection; adherence
card handed to nurse at the weekly clinic visit.
New cases received Rifater (combined rifampicin-isoniazid-pyrazinamide) for 8 weeks
followed by Rifinah 4 (combined rifampicin-isoniazid) plus additional isoniazid for 18
weeks
Retreatment participants received Rifater plus ethambutol for 12 weeks and Rifinah plus
rifampicin-ethambutol for 22 weeks
Outcomes 1. “Successful treatment” included those who were cured and those who completed
treatment; “cured” applied to those who converted from a positive smear or culture, or
both, to a negative smear or culture, or both, at the end of treatment (6 months for
new participants and 8 months for re-treatment participants); “treatment completed”
referred to participants who (a) completed the full course of treatment but had no
pretreatment or post-treatment bacteriological results; (b) had negative pretreatment
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Zwarenstein 1998 ZAF (Continued)
results and had been treated on clinical grounds; or (c) had positive pretreatment
results, negative results after 2 months and no post-treatment results.
2. “Treatment failure” applied to participants with a positive smear or culture at the
end of treatment.
3. “Treatment interrupters” applied to participants who stopped taking treatment for
8 or more weeks during the treatment period.
4. Transfer to another treatment facility.
5. Death from TB or other causes while on treatment.
Notes Location: 1 trial in each of 2 low-income communities near Cape Town, South Africa
Date: 1994 to 1995.
Results combined.
54 participants in 1 trial allocated to community supervision not reported in this paper
Exclusions from analysis: trial 1 (6 cases of multiple drug resistance) and trial 2 (12 cases
of multiple drug resistance and 6 not TB)
Number of exclusions per arm of the 2 trials not given.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random sequence generated by a com-
puter algorithm”.
Allocation concealment (selection bias) Low risk “Consecutively numbered opaque sealed
envelops were used”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information on whether there
was any blinding or not
Incomplete outcome data (attrition bias)
All outcomes
High risk There was differential exclusions between
the intervention and control arms
Selective reporting (reporting bias) Low risk All outcomes stated in themethodology are
reported.
Other bias Unclear risk Not applicable.
Zwarenstein 2000 ZAF
Methods Generation of allocation sequence: computer-generated random numbers
Allocation concealment: consecutively numbered, opaque, sealed envelopes
Blinding: none.
Completeness of follow-up: not stated.
Participants Number: 174 randomized.
Included: newor re-treatment participants aged 15+whowere sputumor culture positive
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Zwarenstein 2000 ZAF (Continued)
Interventions 1. DOT by clinic nurses (see Zwarenstein 1998 ZAF).
2. Self-administration (see Zwarenstein 1998 ZAF).
3. DOT by lay health workers: participants took drugs at home of a lay health
worker under supervision; if participant missed treatment for 1 day, a lay health worker
visited participant’s home and if necessary a member of the South African Tuberculosis
Association (SANTA) also visited the participant.
Outcomes As for Zwarenstein 1998 ZAF.
Notes Location: 4 clinics in a township near Cape Town, South Africa
Date: 1994 to 1995.
18 participants excluded from analysis: 12 with multiple-drug resistant TB and 6 not
TB
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generated by a computer
algorithm.
Allocation concealment (selection bias) Low risk Consecutively numbered opaque sealed en-
velopes.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information on whether there
was any blinding or not
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were exclusions though not differen-
tiated between intervention arms
“After exclusion of 12 MDR and six non-
TB patients”.
Selective reporting (reporting bias) Unclear risk All outcomes stated in themethodology are
reported.
Other bias Unclear risk Not applicable.
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Batki 2002 Compareddirect observationpluswithmethadone treatment for injecting druguserswith routineTB treatment
without methadone
Carroll 2004 Before-and-after study; no control group.
Hwang 2004 Not randomized.
Jasmer 2004 Different criteria for allocation to self-administration or direct observation
Lewin 2004 An educational intervention was evaluated.
Malotte 2001 Evaluates incentives for IV drug users within the context of a direct observation programme
Matthew 2002 Cohort study.
Moulding 2002 Trial evaluating devices that monitor treatment using uranium along a strip of photographic film
Pungrassami 2002a Not randomly allocated; A publication reporting same data as Pungrassami 2002b.
Pungrassami 2002b Not randomly allocated; A publication reporting same data as Pungrassami 2002a.
Sorete-Abore 2002 Cohort study.
Tandon 2002 Described as a RCT, but the randomization led to very different numbers in the 2 groups; subsequently over
50 participants (out of a total of 379) crossed over from self-treatment to direct observation and were excluded
from the analysis; little detail for the rest of the study provided
Thiam 2007 Multifaceted intervention including DOT.
Toyota 2003 Patients in hospital.
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D A T A A N D A N A L Y S E S
Comparison 1. Directly observed versus self-administered
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cure (negative sputum smear in
last month of Rx in patients
+ve initially)
5 1645 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.91, 1.27]
2 Cure (by intensity of monitoring
in control group)
5 1645 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [1.00, 1.15]
2.1 Monthly monitoring of
patients in self administered
group
2 900 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [1.06, 1.25]
2.2 Once every two weeks
monitoring of patients in
self-administered group
1 497 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.83, 1.12]
2.3 Weekly monitoring of
patients in self-administered
group
2 248 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.68, 1.21]
3 Treatment completion (both
with smear sputum test at end
and those without)
6 1839 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.96, 1.19]
4 Treatment completion (grouped
by frequency of monitoring in
the self-administered therapy
group)
6 1839 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.96, 1.19]
4.1 Monthly monitoring of
self-administered treatment
3 1073 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.95, 1.31]
4.2 Once every two weeks
monitoring of self-administered
treatment
1 497 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.14]
4.3 Weekly monitoring of
self-administered treatment
2 269 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.74, 1.46]
Comparison 2. Home observed versus clinic observed
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cure (having a negative sputum
smear test in the last month
of treatment having been
smear-positive initially)
4 1556 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.88, 1.18]
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2 Treatment completion (both
with smear sputum test at end
and those without)
3 1034 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.91, 1.17]
3 Cure (stratified by intensity of
observation)
4 1556 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.91, 1.11]
3.1 DOT (Intense supervision
of observer)
1 522 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.91, 1.28]
3.2 Routine supervision of
DOT
3 1034 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.86, 1.10]
Comparison 3. Community observed vs family observed
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cure (having a negative sputum
smear test in the last month
of treatment having been
smear-positive initially)
2 1493 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.86, 1.21]
2 Treatment completion (both
with smear sputum test at end
and those without)
2 1493 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.90, 1.22]
Comparison 4. Injecting drug users
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment completion 1 300 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.88, 1.13]
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Analysis 1.1. Comparison 1 Directly observed versus self-administered, Outcome 1 Cure (negative sputum
smear in last month of Rx in patients +ve initially).
Review: Directly observed therapy for treating tuberculosis
Comparison: 1 Directly observed versus self-administered
Outcome: 1 Cure (negative sputum smear in last month of Rx in patients +ve initially)
Study or subgroup
Directly
Observed
Therapy
Self
administered
therapy Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Zwarenstein 2000 ZAF (1) 31/54 9/22 7.2 % 1.40 [ 0.81, 2.44 ]
Zwarenstein 1998 ZAF (2) 42/111 31/61 14.0 % 0.74 [ 0.53, 1.05 ]
Kamolratanakul 1999 THA (3) 315/414 283/422 32.1 % 1.13 [ 1.04, 1.24 ]
Walley 2001 PAK (4) 199/335 100/162 27.3 % 0.96 [ 0.83, 1.12 ]
Hsieh 2008 TWN (5) 30/32 22/32 19.5 % 1.36 [ 1.06, 1.75 ]
Total (95% CI) 946 699 100.0 % 1.08 [ 0.91, 1.27 ]
Total events: 617 (Directly Observed Therapy), 445 (Self administered therapy)
Heterogeneity: Tau2 = 0.02; Chi2 = 12.44, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours self administered Favours directly observed
(1) Directly observed patients visited nurses at a clinic or lay health workers at their home
(2) Directly observed patients had to visit a clinic
(3) Directly Observed patients chose observer. In the initial 2 months, DO had more intense contact.
(4) Directly observed patients observed by healthworkers at clinic, or community health workers or family members at home.
(5) Directly observed patients observed by case manager for first two months only
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Analysis 1.2. Comparison 1 Directly observed versus self-administered, Outcome 2 Cure (by intensity of
monitoring in control group).
Review: Directly observed therapy for treating tuberculosis
Comparison: 1 Directly observed versus self-administered
Outcome: 2 Cure (by intensity of monitoring in control group)
Study or subgroup
Directly
Observed
Therapy
Self
administered
therapy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monthly monitoring of patients in self administered group
Hsieh 2008 TWN 30/32 22/32 4.5 % 1.36 [ 1.06, 1.75 ]
Kamolratanakul 1999 THA (1) 315/414 283/422 57.2 % 1.13 [ 1.04, 1.24 ]
Subtotal (95% CI) 446 454 61.7 % 1.15 [ 1.06, 1.25 ]
Total events: 345 (Directly Observed Therapy), 305 (Self administered therapy)
Heterogeneity: Chi2 = 1.87, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 3.38 (P = 0.00071)
2 Once every two weeks monitoring of patients in self-administered group
Walley 2001 PAK (2) 199/335 100/162 27.5 % 0.96 [ 0.83, 1.12 ]
Subtotal (95% CI) 335 162 27.5 % 0.96 [ 0.83, 1.12 ]
Total events: 199 (Directly Observed Therapy), 100 (Self administered therapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
3 Weekly monitoring of patients in self-administered group
Zwarenstein 1998 ZAF (3) 42/111 31/61 8.2 % 0.74 [ 0.53, 1.05 ]
Zwarenstein 2000 ZAF (4) 31/54 9/22 2.6 % 1.40 [ 0.81, 2.44 ]
Subtotal (95% CI) 165 83 10.8 % 0.90 [ 0.68, 1.21 ]
Total events: 73 (Directly Observed Therapy), 40 (Self administered therapy)
Heterogeneity: Chi2 = 3.66, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.68 (P = 0.49)
Total (95% CI) 946 699 100.0 % 1.07 [ 1.00, 1.15 ]
Total events: 617 (Directly Observed Therapy), 445 (Self administered therapy)
Heterogeneity: Chi2 = 12.44, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 1.93 (P = 0.054)
Test for subgroup differences: Chi2 = 5.98, df = 2 (P = 0.05), I2 =67%
0.1 0.2 0.5 1 2 5 10
Favours SAT Favours directly observed
members.
(1) Kamolratanakul 1999 THA: Participants were able to choose to be observed by health workers at clinic, or community members or family members in their own
home. 85% chose family
(2) Walley 2001 PAK: Participants were allocated to observation by healthworkers at clinic, or community health workers or family members at home.
(3) Zwarenstein 1998 ZAF: For directly observed therapy patients had to visit a clinic 5 times a week for 8 weeks then three times a week until treatment completion
(4) Zwarenstein 2000 ZAF: For directly observed therapy patients were required to visit nurses at a clinic (as above) or visit lay health workers at their home
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Analysis 1.3. Comparison 1 Directly observed versus self-administered, Outcome 3 Treatment completion
(both with smear sputum test at end and those without).
Review: Directly observed therapy for treating tuberculosis
Comparison: 1 Directly observed versus self-administered
Outcome: 3 Treatment completion (both with smear sputum test at end and those without)
Study or subgroup
Directly
Observed
Therapy
Self
administered
therapy Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Zwarenstein 1998 ZAF (1) 60/111 50/83 12.1 % 0.90 [ 0.70, 1.15 ]
Zwarenstein 2000 ZAF (2) 40/53 13/22 6.4 % 1.28 [ 0.87, 1.87 ]
Kamolratanakul 1999 THA (3) 347/414 320/422 29.4 % 1.11 [ 1.03, 1.18 ]
Walley 2001 PAK (4) 216/335 105/162 21.4 % 0.99 [ 0.87, 1.14 ]
MacIntyre 2003 AUS (5) 65/87 67/86 18.5 % 0.96 [ 0.81, 1.13 ]
Hsieh 2008 TWN (6) 31/32 22/32 12.3 % 1.41 [ 1.11, 1.79 ]
Total (95% CI) 1032 807 100.0 % 1.07 [ 0.96, 1.19 ]
Total events: 759 (Directly Observed Therapy), 577 (Self administered therapy)
Heterogeneity: Tau2 = 0.01; Chi2 = 11.63, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours self administered Favours directly observed
reporting of outcomes
of outcomes
was a more intense supervision of observers in the intensive phase.
phase
(1) Zwarenstein 1998 ZAF: For directly observed therapy patients had to visit a clinic 5 times a week for 8 weeks then three times a week until treatment completion,
there was incomplete
(2) Zwarenstein 2000 ZAF: For directly observed therapy patients were required to visit nurses at a clinic (as above) or visit lay health workers at their home; there was
incomplete reporting
(3) Kamolratanakul 1999 THA: Participants were able to choose to be observed by health workers at clinic, or community members or family members in their own
home. 85% chose family members.There
(4) Walley 2001 PAK: Participants were allocated to observation by health workers at clinic, or community health workers or family members at home. observation was
during the intensive
(5) This trial used alternate allocation method, there were weekly calls by nurses to the patients observed by a family member
(6) Case manager directly supervised medicine intake for first two months (Intensive phase),
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Analysis 1.4. Comparison 1 Directly observed versus self-administered, Outcome 4 Treatment completion
(grouped by frequency of monitoring in the self-administered therapy group).
Review: Directly observed therapy for treating tuberculosis
Comparison: 1 Directly observed versus self-administered
Outcome: 4 Treatment completion (grouped by frequency of monitoring in the self-administered therapy group)
Study or subgroup
Directly
Observed
Therapy
Self
administered
therapy Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Monthly monitoring of self-administered treatment
Kamolratanakul 1999 THA (1) 347/414 320/422 29.4 % 1.11 [ 1.03, 1.18 ]
MacIntyre 2003 AUS 65/87 67/86 18.5 % 0.96 [ 0.81, 1.13 ]
Hsieh 2008 TWN 31/32 22/32 12.3 % 1.41 [ 1.11, 1.79 ]
Subtotal (95% CI) 533 540 60.2 % 1.12 [ 0.95, 1.31 ]
Total events: 443 (Directly Observed Therapy), 409 (Self administered therapy)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.68, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Once every two weeks monitoring of self-administered treatment
Walley 2001 PAK (2) 216/335 105/162 21.4 % 0.99 [ 0.87, 1.14 ]
Subtotal (95% CI) 335 162 21.4 % 0.99 [ 0.87, 1.14 ]
Total events: 216 (Directly Observed Therapy), 105 (Self administered therapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
3 Weekly monitoring of self-administered treatment
Zwarenstein 1998 ZAF (3) 60/111 50/83 12.1 % 0.90 [ 0.70, 1.15 ]
Zwarenstein 2000 ZAF (4) 40/53 13/22 6.4 % 1.28 [ 0.87, 1.87 ]
Subtotal (95% CI) 164 105 18.4 % 1.04 [ 0.74, 1.46 ]
Total events: 100 (Directly Observed Therapy), 63 (Self administered therapy)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 1032 807 100.0 % 1.07 [ 0.96, 1.19 ]
Total events: 759 (Directly Observed Therapy), 577 (Self administered therapy)
Heterogeneity: Tau2 = 0.01; Chi2 = 11.63, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Chi2 = 1.16, df = 2 (P = 0.56), I2 =0.0%
0.05 0.2 1 5 20
Favours self administered Favours directly observed
members.
(1) Kamolratanakul 1999 THA: Participants were able to choose to be observed by health workers at clinic, or community members or family members in their own
home. 85% chose family
(2) Walley 2001 PAK: Participants were allocated to observation by healthworkers at clinic, or community health workers or family members at home.
(3) Zwarenstein 1998 ZAF: For directly observed therapy patients had to visit a clinic 5 times a week for 8 weeks then three times a week until treatment completion
(4) Zwarenstein 2000 ZAF: For directly observed therapy patients were required to visit nurses at a clinic (as above) or visit lay health workers at their home
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Analysis 2.1. Comparison 2 Home observed versus clinic observed, Outcome 1 Cure (having a negative
sputum smear test in the last month of treatment having been smear-positive initially).
Review: Directly observed therapy for treating tuberculosis
Comparison: 2 Home observed versus clinic observed
Outcome: 1 Cure (having a negative sputum smear test in the last month of treatment having been smear-positive initially)
Study or subgroup Home based Clinic based Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Zwarenstein 2000 ZAF (1) 31/54 24/58 11.5 % 1.39 [ 0.95, 2.03 ]
Walley 2001 PAK (2) 91/165 108/170 29.5 % 0.87 [ 0.73, 1.04 ]
Lwilla 2003 TZA (3) 117/221 148/301 30.8 % 1.08 [ 0.91, 1.28 ]
Wandwalo 2004 TZA (4) 111/260 141/327 28.2 % 0.99 [ 0.82, 1.19 ]
Total (95% CI) 700 856 100.0 % 1.02 [ 0.88, 1.18 ]
Total events: 350 (Home based), 421 (Clinic based)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.98, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours clinic observed Favours home observed
(1) For directly observed patients, observation continued in the consolidated phase
(2) For directly observed patients, observation only during the intensive phase
(3) For directly observed patients, this was only during the the intensive phase; there was additional monthly supervision by district co-orrdinator
(4) For directly observed patients, observation was only during the intensive phase
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Analysis 2.2. Comparison 2 Home observed versus clinic observed, Outcome 2 Treatment completion
(both with smear sputum test at end and those without).
Review: Directly observed therapy for treating tuberculosis
Comparison: 2 Home observed versus clinic observed
Outcome: 2 Treatment completion (both with smear sputum test at end and those without)
Study or subgroup Home based Clinic based Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Walley 2001 PAK (1) 103/165 113/170 31.2 % 0.94 [ 0.80, 1.10 ]
Wandwalo 2004 TZA (2) 221/260 271/327 53.2 % 1.03 [ 0.96, 1.10 ]
Zwarenstein 2000 ZAF (3) 40/54 33/58 15.5 % 1.30 [ 0.99, 1.71 ]
Total (95% CI) 479 555 100.0 % 1.04 [ 0.91, 1.17 ]
Total events: 364 (Home based), 417 (Clinic based)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.08, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours clinic observed Favours home observed
(1) observation was during the intensive phase
(2) observation was during the intensive phase
(3) Observation continued even in the consolidated phase
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Analysis 2.3. Comparison 2 Home observed versus clinic observed, Outcome 3 Cure (stratified by intensity
of observation).
Review: Directly observed therapy for treating tuberculosis
Comparison: 2 Home observed versus clinic observed
Outcome: 3 Cure (stratified by intensity of observation)
Study or subgroup Home based Clinic based Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DOT (Intense supervision of observer)
Lwilla 2003 TZA 117/221 148/301 33.0 % 1.08 [ 0.91, 1.28 ]
Subtotal (95% CI) 221 301 33.0 % 1.08 [ 0.91, 1.28 ]
Total events: 117 (Home based), 148 (Clinic based)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
2 Routine supervision of DOT
Walley 2001 PAK 91/165 108/170 28.0 % 0.87 [ 0.73, 1.04 ]
Wandwalo 2004 TZA 111/260 141/327 32.9 % 0.99 [ 0.82, 1.19 ]
Zwarenstein 2000 ZAF 31/54 24/58 6.1 % 1.39 [ 0.95, 2.03 ]
Subtotal (95% CI) 479 555 67.0 % 0.98 [ 0.86, 1.10 ]
Total events: 233 (Home based), 273 (Clinic based)
Heterogeneity: Chi2 = 4.91, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 700 856 100.0 % 1.01 [ 0.91, 1.11 ]
Total events: 350 (Home based), 421 (Clinic based)
Heterogeneity: Chi2 = 5.98, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Chi2 = 0.86, df = 1 (P = 0.35), I2 =0.0%
0.01 0.1 1 10 100
Favours home Favours clinic
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Analysis 3.1. Comparison 3 Community observed vs family observed, Outcome 1 Cure (having a negative
sputum smear test in the last month of treatment having been smear-positive initially).
Review: Directly observed therapy for treating tuberculosis
Comparison: 3 Community observed vs family observed
Outcome: 1 Cure (having a negative sputum smear test in the last month of treatment having been smear-positive initially)
Study or subgroup
Community
observed Family observed Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wright 2004 SWZ (1) 198/290 182/296 45.0 % 1.11 [ 0.99, 1.25 ]
Newell 2006 NPL (2) 465/549 319/358 55.0 % 0.95 [ 0.90, 1.00 ]
Total (95% CI) 839 654 100.0 % 1.02 [ 0.86, 1.21 ]
Total events: 663 (Community observed), 501 (Family observed)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.92, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours family observed Favours comm. observed
(1) For direcly observed patients, observation was at the health workers’ home
(2) The community health worker visited the patient at home, % occasionally patients came to the health workers’ home
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Analysis 3.2. Comparison 3 Community observed vs family observed, Outcome 2 Treatment completion
(both with smear sputum test at end and those without).
Review: Directly observed therapy for treating tuberculosis
Comparison: 3 Community observed vs family observed
Outcome: 2 Treatment completion (both with smear sputum test at end and those without)
Study or subgroup
Community
observed Family observed Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Newell 2006 NPL (1) 527/549 344/358 55.5 % 1.00 [ 0.97, 1.03 ]
Wright 2004 SWZ (2) 214/290 197/296 44.5 % 1.11 [ 1.00, 1.23 ]
Total (95% CI) 839 654 100.0 % 1.05 [ 0.90, 1.22 ]
Total events: 741 (Community observed), 541 (Family observed)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.92, df = 1 (P = 0.005); I2 =87%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours family observed Favours comm. observed
(1) The community health worker visited the patient at their homes;occasionally the patients came to the HW home
(2) Obsevation was at the health workers home
Analysis 4.1. Comparison 4 Injecting drug users, Outcome 1 Treatment completion.
Review: Directly observed therapy for treating tuberculosis
Comparison: 4 Injecting drug users
Outcome: 1 Treatment completion
Study or subgroup Directly observed Self administered Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chaisson 2001 USA 158/200 79/100 100.0 % 1.00 [ 0.88, 1.13 ]
Total (95% CI) 200 100 100.0 % 1.00 [ 0.88, 1.13 ]
Total events: 158 (Directly observed), 79 (Self administered)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours self administered Favours directly observed
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A D D I T I O N A L T A B L E S
Table 1. Summary of interventions in trials of DOT versus self-administered
Trial ID DOT Self administered therapy
Who ob-
served?
Where? How often? Adher-
ence
recorded
at each
contact
Cure Frequency
of contact
with
health ser-
vice
Adher-
ence
recorded
at each
contact
Cure
Intensive
phase
Consoli-
dation
phase
Zwaren-
stein
1998 ZAF
Nurses Clinic 5 times per
week
3 times per
week
Yes 38%
(42/111)
Weekly Yes 51%
(31/61
Zwaren-
stein
2000 ZAF
Nurse Clinic 5 times per
week
3 times per
week
Yes 57%
(31/54)
Weekly Yes 41%
(9/22)
Lay health
worker
Lay health
workers
home
Kamol-
ratanakul
1999 THA
1
Healthcare
worker
Clinic Daily Daily Yes 76%
(315/414)
Monthly Unclear 67%
(283/422)
Commu-
nity health
worker
Home Daily Daily
Family
member
Home Daily Daily
Walley
2001 PAK
Healthcare
worker
Clinic 6 times per
week
2 times per
month
Yes 59%
(199/335)
Every two
weeks
Unclear 62%
(100/162)
Commu-
nity health
worker
Home
Family
member
Home Daily Daily
MacIntyre
2003 AUS
2
Family
member
Home Daily Daily Yes Not
reported
Monthly Yes Not
reported
Hsieh
2008
TWN 3
Case man-
ager or
Hospital
care
Hospital Daily Once per
week
Yes 94%
(30/32)
Monthly
unsched-
uled visit
Yes 69%
(22/32)
1In Kamolratanakul 1999 THA patients could choose which observer they preferred and there a more intense supervision of observers
in the intensive phase.
2In MacIntyre 2003 AUS nurses made weekly calls to the patients who were observed by a family member.
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3In Hsieh 2008 TWN the case manager directly supervised medicine intake for first two months (Intensive phase), then self-adminis-
tration with weekly unscheduled visit.
Table 2. Interventions comparing home versus clinic direct observation
Trial ID DOT at patient’s home DOT at clinic
Who ob-
served?
How often? Supervi-
sion of ob-
server
Cure Who ob-
served?
How often? Cure
Intensive
phase
Consoli-
dation
phase
Intensive
phase
Consoli-
dation
phase
Walley
2001 PAK
1
Family
member
Daily Not
described
Observers
collected
drugs from
the
clinic every
2 weeks
55%
(91/165)
Health
worker
6 times per
week
Self-
supervised
64%
(108/170)
Wandwalo
2004 TZA
1
Family
member or
former TB
patient
Daily Self-
supervised
Observers
collected
drugs
from clinic
weekly and
spot
checks
were con-
ducted by
health
worker
43%
(111/260)
Health
worker
Daily Self-
supervised
43%
(141/327)
Zwaren-
stein
2000 ZAF
Lay health
worker2
’Sev-
eral times a
week’
Not
described
Observer
collected
drugs
monthly
57%
(31/54)
Health
worker
5 times a
week
3 times a
week
41%
(24/58)
Lwilla
2003 TZA
1
Commu-
nity volun-
teer
Daily Self-
supervised
Observer
was visited
every two
weeks by
the health
worker and
ev-
ery month
by the dis-
trict co-or-
dinator3
53%
(117/221)
Health
worker
Daily Self-
supervised
49%
(148/301)
1In Lwilla 2003 TZA, Walley 2001 PAK and Wandwalo 2004 TZA observation was during the intensive phase, while in the clinic
observation arm of Zwarenstein 2000 ZAF it continued in the consolidated phase.
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2In Zwarenstein 2000 ZAF the observation took place in the lay health worker’s home, not the patient’s home.
3In Lwilla 2003 TZA there was additional supervision by the district coordinator.
Table 3. Interventions comparing family-administered DOT versus community health worker DOT
Trial ID Who ob-
served?
Where? How often? Addi-
tional in-
tervention
Who ob-
served?
Where? How often?
Intensive
phase
Consoli-
dation
phase
Intensive
phase
Consoli-
dation
phase
Newell
2006 NPL
Family
member
Patient’s
home
Daily Daily Drugs sup-
plied to su-
pervisor
every week
Commu-
nity health
worker
Patient’s
home1
Daily Daily
Wright
2004
SWZ
Family
member
Patient’s
home
Daily Daily Patient re-
viewed
at the diag-
nostic cen-
tre once
per month
Recorded
in a patient
adherence
card
Commu-
nity health
worker
Commu-
nity health
worker’s
home
Daily Daily
1In Newell 2006 NPL the community health worker mainly visited the patients at their homes but occasionally the patients came to
the health worker’s home.
A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 tuberculosis tuberculosis tuberculosis tuberculosis tuberculosis
2 DOT* PATIENTCOMPLI-
ANCE
PATIENTCOMPLI-
ANCE
PATIENTCOMPLI-
ANCE
DOT*
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(Continued)
3 directly observed
therapy
PATIENT PARTICI-
PATION
PATIENT PARTICI-
PATION
PATIENT
MONITORING
supervision
4 2 or 3 patient monitoring MOTIVATION DOT$ 2 or 3
5 1 and 4 MOTIVATION DE-
CISION SUPPORT
TECHNIQUES
directly observed
therapy
1 and 4
6 - DE-
CISION SUPPORT
TECHNIQUES
DOT* compliance -
7 - DOT* directly observed
therapy
motivation -
8 - directly observed
therapy
compliance patient$ -
9 - compliance patient* defaulter$ -
10 - defaulter* defaulter* adheren$ -
11 - adheren* adheren* supervis$ -
12 - supervision* supervis* 2-11/or -
13 - 2-12/or 2-12/or 1 and 12 -
14 - 1 and 13 1 and 13 Limit 13 to human -
15 - - Limit 14 to human - -
aCIDG Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane (Higgins 2011); upper case:
MeSH or EMTREE heading; lower case: free text term.
WH A T ’ S N E W
Last assessed as up-to-date: 13 January 2015.
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Date Event Description
13 May 2015 New search has been performed We added a trial and a table documenting in detail the
inputs to the intervention and control groups. Also, we
constructed ’Summary of findings’ tables and carried out
additional analyses investigating possible effects of con-
founding by intense health worker contacts. We rewrote
the review and conclusions
13 May 2015 New citation required but conclusions have not changed One trial was added and summary of findings tables were
constructed
H I S T O R Y
Protocol first published: Issue 4, 2001
Review first published: Issue 4, 2001
Date Event Description
11 August 2011 New search has been performed Categorised as Current question - no update intended
(results conclusive). See “Published notes” section for
details
10 August 2011 Amended Pilot classification system added; explanation provided
in “published notes” section
19 September 2008 Amended Converted to new review format with minor editing.
13 August 2007 New citation required and conclusions have changed 2007, Issue 4: One new trial included (Newell 2006
NPL). Also added references to new tuberculosis ad-
herence reviews in the ’Background’ section and re-
worded objectives to clarify that the review encom-
passes comparisons between different types of directly
observed therapy
15 February 2006 Amended 2006, Issue 2 (Volmink 2006): Four new trials in-
cluded (Lwilla 2003 TZA; MacIntyre 2003 AUS;
Wandwalo 2004 TZA; Wright 2004 SWZ).
19 November 2003 New citation required and conclusions have changed 2003, Issue 1: Two trials added (Chaisson 2001 USA;
Malotte 2001 USAa).
8 August 2001 New citation required and major changes 2001, Issue 4 (Volmink 2001): first version of this
review on directly observed therapy
2000, Issue 4 (Volmink 2000a): original review split
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(Continued)
into a series of Cochrane Reviews, each focusing on
particular intervention promotion strategies, such as
directly observed therapy in this review
1997, Issue 2: review first published as ’Interventions
for promoting adherence to tuberculosis management’
C O N T R I B U T I O N S O F A U T H O R S
Jimmy Volmink and Paul Garner carried out the first edition of this Cochrane Review (Volmink 2001) and review updates (Volmink
2003; Volmink 2006; Volmink 2007). Jamlick Karumbi performed this review update, assisted by Paul Garner. All review authors
reviewed and approved the final manuscript.
D E C L A R A T I O N S O F I N T E R E S T
As a result of the earlier editions of this review from the mid 1990s, PG has become recognised and associated with the continued
debate about whether DOT should be central to national programmes in low- and middle-income countries.
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• South African Medical Research Council, South Africa.
• Liverpool School of Tropical Medicine, UK.
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• Department for International Development, UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Directly Observed Therapy; Antitubercular Agents [∗therapeutic use]; Randomized Controlled Trials as Topic; Tuberculosis, Pul-
monary [∗drug therapy]
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